Topics

Centers for Disease Control and Prevention

3:29 a.m. Nov. 19, 2021 - By Tomi Kilgore
Moderna COVID-19 vaccine booster gets FDA OK for all adultsShare of Moderna Inc. shot up 6.0% in premarket trading Friday, after the biotechnology company said the U.S. Food and Drug Administration has extended the emergency use authorization (EUA) of a booster dose of its COVID-19 vaccine to all adults, aged 18 and older. The booster dose is for those who have completed COVID-19 vaccinations, with any authorized or approved vaccine, at least six months ago. "This emergency use authorization comes at a critical time as we enter the winter months and face increasing COVID-19 case counts and hospitalizations across the country," said Moderna Chief Executive Stéphane Bancel. Next, an advisory committee of the U.S. Centers for Disease Control and Prevention (CDC) will meet to discuss a potential recommendation for rolling out COVID-19 boosters. Moderna's stock has tumbled 33.1% over the past three months through Thursday but has soared 140.7% year to date, while the S&P 500 has gained 25.3% this year.
1:24 a.m. Nov. 1, 2021 - By Ciara Linnane
Moderna says FDA needs more time to review COVID vaccine in 12-to-17-year oldsModerna Inc. said it would delay filing a request with the U.S. Food and Drug Administration to emergency use authorization of its COVID-19 vaccine at the 50 µg dose level in children ages 6 to 11, to give the regulator time to complete its review of an earlier submission for use in adolescents 12 to 17 years of age. The company announced the news in a Sunday release, in which it said the FDA had informed it that it needed more time to complete its assessment of the request for the 100 µg dose level in 12-to-17-year-olds. The agency told Moderna late Friday that it would need more time to review the data on the risk of myocarditis after vaccination. It said the review may not be completed before January of 2022. "An increased risk of myocarditis has been described for COVID-19 vaccines, including the Moderna COVID-19 vaccine, particularly in young men and following the second dose," the company said. It noted that both the U.S. Centers for Disease Control and Prevention and the World Health Organization have said that myocarditis following vaccination with mRNA vaccines has been "rare and generally mild." About 1.5 million adolescents have received the Moderna vaccine and the rare condition has been showed to be an increased risk in that age group, said the release. Moderna shares were down 2.2% premarket but have gained 240% in the year to date, while the SPDR S&P Biotech ETF has fallen 11% and the S&P 500 has gained 22.6%.
3:48 a.m. Oct. 20, 2021 - By Jaimy Lee
White House: Children will be able to get COVID-19 shots from their pediatriciansThe White House on Wednesday announced a plan detailing how the U.S. plans to roll out COVID-19 vaccines for children between the ages of 5 and 11 years old if and when COVID-19 shots are authorized for this age group. White House officials said there is enough vaccine to immunize all 28 million children in this age group, and kids will be able to get a shot at 25,000 pediatricians' offices, in addition to 100 children's hospitals, "tens of thousands" of pharmacies, and some school and community sites. A Food and Drug Administration advisory committee is scheduled to meet Tuesday to discuss BioNTech SE and Pfizer Inc.'s application for authorization for elementary school-aged children; it will vote on whether the vaccine is safe and effective in this age group, and then the FDA will issue its decision. The Centers for Disease Control and Prevention also has to weigh in.
8:16 a.m. Sept. 24, 2021 - By Jaimy Lee
CDC: We are not changing the definition of 'fully vaccinated' now that COVID-19 boosters are available The Centers for Disease Control and Prevention does not plan to change the definition of what it means to be "fully vaccinated" right now that BioNTech SE and Pfizer Inc.'s COVID-19 booster shots are available for a large group of the U.S. population. During a White House briefing on Friday, CDC director Rochelle Walensky said "we need to have more experience with our third shot and have more people eligible or recommended to receive it, before we change that definition." The Food and Drug Administration on Wednesday authorized a third booster dose of Pfizer's two-dose vaccine, making it the first vaccine to receive regulatory authorization for a booster. Moderna Inc.'s application for a booster shot for its two-dose vaccine is currently under review at the FDA.
2:34 a.m. Sept. 22, 2021 - By Jaimy Lee
CDC committee to meet today and Thursday to again discuss BioNTech and Pfizer's COVID-19 boosterA Centers for Disease Control and Prevention committee is Wednesday and Thursday to again discuss the science and possible administration plan for BioNTech SE and Pfizer Inc.'s COVID-19 booster shot. The CDC's Advisory Committee on Immunization Practices sets out the guidelines for how vaccines should be used in the U.S. The Food and Drug Administration has not approved or authorized an extra dose of the BioNTech and Pfizer vaccine except in people who are immuno-compromised, and an influential FDA committee last week recommended that boosters to older people and those who are at higher risk of severe disease. Some experts have suggested that the FDA decision is coming this week.
4:29 a.m. Sept. 15, 2021 - By Jaimy Lee
Pfizer cites 'totality' of clinical data in bid for COVID-19 booster approvalShares of Pfizer Inc. gained 0.1% in premarket trading on Wednesday after the drug maker said the "totality" of clinical data indicates that people who are at least 16 years old and were vaccinated with the COVID-19 shot that it developed with BioNTech SE should get a booster after six months. In a published Wednesday morning by the Food and Drug Administration in advance of an advisory committee meeting set for Friday, Pfizer said its Phase 3 substudy examined 306 people between the ages of 18 and 55 years old who got a third dose. It found that an extra dose is considered safe and increased neutralizing antibody titers against the original strain of the virus as well as the beta and delta variants to a higher rate than what was reported after two doses in the clinical trials last year. Younger participants were more likely to report systemic events after the second and third doses than the first dose; fever was more common after the third dose. No adverse events were reported in the first month after the third dose. Pfizer also cited research conducted by Israel, the Centers for Disease Control and Prevention, and the hospital system Kaiser Permanente in the document, saying that data from Israel "suggest reduced effectiveness against severe disease could eventually follow observed reductions in effectiveness against SARS-CoV-2 infections." Pfizer's stock is up 21.4% this year, while the S&P 500 has gained 18.9%.
10:46 a.m. Sept. 2, 2021 - By Jaimy Lee
FDA committee to discuss COVID-19 booster shotsAn influential Food and Drug Administration advisory committee plans to meet Sept. 17 to discuss extra doses of the COVID-19 vaccines, including the application filed by BioNTech SE and Pfizer Inc. for a third dose of their COVID-19 shot. Moderna Inc. on Wednesday also submitted its application for a booster dose of its COVID-19 vaccine. The FDA's Vaccines and Related Biological Products Advisory Committee traditionally recommends whether the FDA should authorize or approve a vaccine or drug. The regulator is not required to follow the advice of the committee but it often does. The Biden administration previously said that COVID-19 booster shots will be available to adults starting Sept. 20, though from the FDA and the Centers for Disease Control and Prevention. "The FDA will review the supplemental application as expeditiously as possible, while still doing so in a thorough and science-based manner," Dr. Peter Marks, the director of the FDA's Center for Biologics Research and Evaluation, said in a on Wednesday.
3:14 a.m. June 22, 2021 - By Jaimy Lee
CDC committee to discuss rare cases of myocarditis occurring in people who have gotten their COVID-19 shotsFederal health experts plan to meet on Wednesday and Thursday rare but serious cases of myocarditis and pericarditis - inflammation of the heart - reported in about 800 people who have been vaccinated against COVID-19 with the Moderna Inc. or Pfizer Inc. mRNA vaccines, as of June 12. More than half of those cases occurred in people younger than 30, including about 75 teens, according to by Centers for Disease Control and Prevention officials. Though the cases of myocarditis are considered concerning, these cases are also very rare, occurring out of the roughly 300 million doses that have been administered in the U.S. The CDC's Advisory Committee on Immunization Practices is the same committee that recommends whether authorized or approved vaccines should be given to Americans. It met earlier this year to discuss safety concerns about Johnson & Johnson's COVID-19 shot.
6:40 a.m. June 4, 2021 - By Jaimy Lee
CDC director is 'concerned' about teens hospitalized for COVID-19, urges vaccinationThe Centers for Disease Control and Prevention is urging teens who are at least 12 years old to get vaccinated over concerns about the number of adolescents who are being hospitalized for COVID-19. The Pfizer Inc. and BioNTech SE vaccine was authorized in mid-May for teens between the ages of 12 and 15 years old. (It had already been authorized for those who are at least 16 years old since December.) "I am deeply concerned by the numbers of hospitalized adolescents and saddened to see the number of adolescents who required treatment in intensive care units or mechanical ventilation," CDC director Dr. Rochelle Walensky said in a statement. published Friday by the CDC said COVID-19 hospitalization rates among teens increased in March and April. About 200 teens were hospitalized for COVID-19 in 14 states between January and March of this year, 64 of whom were admitted to the intensive care unit during their stays.
3:15 a.m. June 1, 2021 - By Jaimy Lee
Abbott adjusts financial outlook, citing lower demand for COVID-19 testsShares of Abbott fell 2.3% in premarket trading on Tuesday after the diagnostics company updated its financial outlook for 2021, citing declining demand for its COVID-19 tests. Abbott said it now expects earnings per share of $2.75 to $2.95 and adjusted EPS of $4.30 to $4.50. The company in April said it projected EPS of at least $3.74 and adjusted EPS of at least $5.00 for the full year. There are a number of reasons why COVID-19 testing volume is declining in the U.S., including increasing vaccination rates and recent guidance from the Centers for Disease Control and Prevention that told vaccinated Americans if they are exposed to someone infected with the virus. Abbott has developed 12 COVID-19 tests, which generated $2.2 billion in the first quarter of the year. Abbott's stock is up 6.5% for the year, while the broader S&P 500 has gained 11.9%.
3:21 a.m. May 25, 2021 - MarketWatch
Moderna's COVID vaccine safe in adolescentsModerna Inc. said its Covid-19 vaccine was effective in children aged 12 to 17 in a new study, a finding that could clear the way for a second shot for use in adolescents. The Cambridge, Mass., company said the vaccine induced immune responses among children that were comparable to those seen in a study of adults last year.
4:01 a.m. May 17, 2021 - By Jaimy Lee
CDC: 3 million teens between ages of 12 and 17 have received at least one COVID-19 shotMore than 3 million teens between the ages of 12 and 17 years old have gotten at least one COVID-19 shot, as of Monday, . The public health agency does not break out more specific age categories on its COVID Data Tracker page; however, it says that about 157 million people over the age of 12 have received one dose of a vaccine, and about 154 million of those shots went to people who are at least 18 years old. the BioNTech SE and Pfizer Inc. two-dose, mRNA vaccine for use in teens between the ages of 12 and 15 years old, making it the first vaccine available in the U.S. to this group of younger teens. (The shot had previously been authorized for anyone who was at least 16 years old.)
5:51 a.m. May 3, 2021 - By Jaimy Lee
Ocugen's stock is up after sharing preprint about COVID-19 vaccine effectiveness against lesser known Brazilian variantShares of Ocugen Inc. were up 20.2% in trading on Monday after the Pennslyvania company said a COVID-19 vaccine it is contracted to develop with Indian biotechnology firm Bharat Biotech International Ltd. is "potentially" effective against B.1.1.28.2, or P.2., a variant first identified in Brazil in April 2020. The variant has been designated a variant of interest in the U.S. but is not considered a more serious variant of concern like the B.1.1.7. out of the U.K. or the P.1, which was also first identified in Brazil, . The cited by Ocugen is a preprint, which is preliminary medical research that has not been peer-reviewed, and it compared IgG antibody titers in people who had received the shots to those who have recovered from COVID-19. The study was conducted in a lab and included 61 sera samples, two of which had the B.1.1.28.2 variant. Ocugen has said it is developing Bharat's vaccine, which was approved in India in January, for the U.S. but has not yet initiated clinical trials for this market. Ocugen's stock has soared 729.8% since the start of the year, while the S&P 500 is up 11.3%.
8:28 p.m. April 18, 2021 - By Quentin Fottrell
The public’s expectation of perfection: Risk of blood clot from Johnson & Johnson COVID-19 vaccine is 0.00009% ‘It’s the same perceptual problem when we blindly drive to the airport texting, yet worry about the airplane’‘It’s the same perceptual problem when we blindly drive to the airport texting, yet worry about the airplane.’
5:06 a.m. April 13, 2021 - By Tomi Kilgore
Moderna, BioNTech stocks surge after regulators halt use of J&J vaccine Shares of Moderna Inc. shot up 8.6% in morning trading, BioNTech SE ran up 5.7% toward a 4-month high and Pfizer Inc. climbed 1.1% toward a 3-month high, after U.S. health regulators paused the use of Johnson & Johnson's COVID-19 vaccine . Meanwhile, J&J shares shed $2.98, or 1.8%, to shave about 20 points of the Dow Jones Industrial Average's price, as the Dow dropped 132 points, or 0.4%. Moderna's two-dose COVID-19 vaccine, and the two-dose vaccine from Pfizer and partner BioNTech are mRNA vaccines while J&J's one-dose vaccine is an adenovirus vaccine. The Centers for Disease Control and Prevention and the Food and Drug Administration said there have been six cases of blood clotting out of the roughly six million people who have received the J&J vaccine, all of who were women between the ages of 18 and 48.
3:36 a.m. March 24, 2021 - By Jaimy Lee
Twist's COVID-19 test, which can detect variants, gets authorizedShares of Twist Bioscience Corp. were down 1.6% in premarket trading on Wednesday after the company said its in-vitro diagnostic test that can detect SARS-CoV-2 RNA received emergency authorization in the U.S. Twist's test can identify the presence of the virus from a patient sample; it can also be used by Biotia Inc.'s software system to analyze the sequence and detect any genetic variants. So-called "variants of concern" have emerged over the last six months, including the B.1.1.7 variant out of the U.K., which is thought to be more infectious and makes % of all new U.S. cases, according to the Centers for Disease Control and Prevention. "This test opens the door to a new diagnostic method and can also guide vaccine research, since it captures viral variants so well," Biotia co-founder Christopher Mason said in a news release. Biota is a privately held company. Twist's stock has soared 390.6% over the past 12 months, while the broader S&P 500 is up 74.8%.
3:32 p.m. March 11, 2021 - By Quentin Fottrell
‘Mask up, America!’ Texas abandons COVID-19 mask mandate — health experts say that’s a really, really bad idea One year after the coronavirus was officially declared a pandemic by the World Health Organization, health professionals have decried moves to go masklessOne year after the coronavirus was officially declared a pandemic by the World Health Organization, health professionals have decried moves to go maskless.
4:34 a.m. Feb. 16, 2021 - By Tomi Kilgore
Moderna moves up expected delivery of 300 million COVID-19 vaccine doses to end of JulyModerna Inc. provided on Tuesday an update of the supply of its COVID-19 vaccine, saying it expects to deliver 100 million doses to the U.S. Government by the end of March. The company said it moved up the expected delivery of its second 100 million doses to the end of May from the end of June, and its third 100 million doses to the end of July, from the end of September. To date, the company said it has delivered 45.4 million doses of its vaccine, and the Centers for Disease Control and Prevention said about 25.5 million doses of the vaccine have been administered. Moderna's vaccine requires two doses, spaced weeks apart. Moderna said it does not plan to stockpile significant quantities of doses to smooth shipments, as it has chosen to ship doses to the government as they are produced. Moderna's stock, which edged up 0.1% in premarket trading, has soared 87.6% over the past three months through Friday, while the S&P 500 has gained 8.5%.
7:56 a.m. Jan. 28, 2021 - By Jaimy Lee
South Carolina officials confirm first two cases of South African variant in the U.S. Health officials in South Carolina confirmed that two people in the state have tested positive for a new coronavirus variant that was first identified in South Africa. These are the first two confirmed cases of the more infectious variant in the U.S. The South African strain, which is called B.1.351, is one of several new variants wthat have emerged around the world and are raising concern among government officials and medical experts over their transmissibility. The South Carolina Department of Health and Environmental Control confirmed the two cases in residents of the Lowcountry and the Pee Dee region in a on Thursday. Neither adult has a travel history, and they do not know each other, officials said. Health departments use genomic sequencing to identify new strains or variants among COVID-19 test samples; this is how the South Carolina health department identified both cases. Another variant, the B.1.1.7, which was first detected in the United Kingdom, has infected more than 300 people in the U.S. so far, according to the from the Centers for Disease Control and Prevention. This variant is also thought to be more infectious. This week, Moderna Inc. said a laboratory study demonstrated that its COVID-19 vaccine against the B.1.351 strain, and Regeneron Pharmaceuticals Inc. said one of the two antibodies used in its COVID-19 treatment .
3:19 a.m. Jan. 26, 2021 - By Ciara Linnane
Moderna on track to deliver 200 million doses of its COVID vaccine to U.S. govt by end-JuneModerna Inc. said Tuesday it is on track to deliver 100 million doses of its COVID-19 vaccine to the U.S. government by end-March and to deliver 200 million doses by end-June. The Cambridge, Mass.-based biotech said it has already delivered more than 30 million doses of the vaccine to the U.S. government. About 10.1 million doses of the vaccine have by now been administered in the U.S., the company said, citing Centers for Disease Control and Prevention data. The vaccine was granted emergency use authorization by the U.S. Food and Drug Administration on Dec. 18, shortly after a separate vaccine developed by Pfizer Inc. and its German partner BioNTech SE won the same authorization. The U.S. government has an option to purchase up to 300 million doses of the Moderna vaccine. The vaccine has also been authorized for use in Canada, Israel, the European Union, the U.K. and Switzerland. Moderna shares were down 1.2% premarket, but have gained 596% in the last 12 months, while the SPDR S&P Biotech ETF has gained 73% and the S&P 500 has gained 17%.
3:24 a.m. Jan. 25, 2021 - By Jaimy Lee
CDC says doses of COVID-19 vaccines can be spaced out by up to 42 daysThe Centers for Disease Control and Prevention updated for vaccine administration to say that it's okay to space out the first and second doses of the currently available COVID-19 vaccines by up to 42 days, if necessary. The regulatory labels say that doses of the BioNTech SE and Pfizer Inc. vaccine should be spaced 21 days apart, while the second dose of Moderna Inc.'s 's vaccine is expected to be administered 28 days after the first dose. "However, if it is not feasible to adhere to the recommended interval, the second dose of Pfizer-BioNTech and Moderna COVID-19 vaccines may be scheduled for administration up to 6 weeks (42 days) after the first dose," the CDC said. The United Kingdom has also said of its authorized vaccines, which include the AstraZeneca and University of Oxford vaccine in addition to the ones developed by BioNTech/Pfizer and Moderna, as needed. Over the past 12 months, BioNTech's stock has rallied 209.9%, Pfizer shares are down 3.1%, and Moderna's stock has soared 520.3%. The S&P 500 has gained 15.6% over the past year.
3:20 a.m. Jan. 25, 2021 - By Jaimy Lee
CDC: Moderna's COVID-19 vaccine can cause allergic reaction in some peopleThe Centers for Disease Control and Prevention said Friday that Moderna Inc.'s COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the agency's findings about the coronavirus vaccine developed by BioNTech SE and Pfizer Inc. . Moderna's stock was up 1.6% in premarket trading on Monday. There were 10 cases of anaphylaxis among the roughly 4 million doses administered between Dec. 21 and Jan. 10, according to the . Both vaccines are mRNA-based vaccines, with similar efficacy rates in clinical trials. They are the only two COVID-19 vaccines that have been authorized in the U.S. so far during the pandemic. The CDC that health care providers prepare for the possibility of anaphylaxis among some people who get vaccinated. Moderna's stock has soared 520.3% over the past 12 months, while the S&P 500 is up 15.6%.
9:50 a.m. Jan. 19, 2021 - By Ciara Linnane
U.S. climbs above 400,000 COVID-19 fatalities as California becomes first state with 3 million confirmed cases L.A. County air quality regulator lifts limit on how many cremations can be performed to help clear backlog of bodiesThe number of global cases of the coronavirus-borne illness COVID-19 rose above 95.9 million on Tuesday, and the U.S. edged closer to 400,000 deaths, with California becoming the first state with more than three million confirmed cases.
9:15 a.m. Jan. 12, 2021 - By Ciara Linnane
U.S. heads toward 23 million COVID-19 cases as three lawmakers test positive after Capitol lockdown News adds to fears that last week’s attack on the U.S. seat of government created two superspreader eventsThe number of confirmed global cases of the coronavirus-borne illness COVID-19 climbed above 91 million on Tuesday, and the U.S. case tally headed toward 23 million, as three Democratic lawmakers who were forced to shelter in place during last week’s attack on the Capitol tested positive for the virus.
12:30 p.m. Jan. 11, 2021 - By Ciara Linnane
U.S. tops 22 million cases of COVID-19 after adding record of more than 300,000 in a day ‘COVID remains out of control in the U.S.,’ analyst saysThe global case tally for the coronavirus illness COVID-19 rose above 90 million on Monday, and the U.S. topped 22 million confirmed cases, after setting a record for new cases in a single day of more than 300,000 on Friday.
12:54 p.m. Jan. 10, 2021 - By Andrew Keshner
What side effects, if any, can you expect from a COVID-19 vaccine shot? Doctors have advised the CDC to be transparent and forthcoming about any side effectsDoctors have advised the CDC to be transparent and forthcoming about any side effects.
1:15 a.m. Jan. 7, 2021 - By Ciara Linnane
U.S. could see up to 150,000 more COVID-19 deaths by February as new strain takes hold, expert warns More infectious variant makes it even more crucial to get vaccine program on track after early disappointment, says Dr. Ashish JhaThe U.S. set a fresh record for hospitalizations with the coronavirus-borne illness COVID-19 on Wednesday, as experts said the new, far more infectious variant makes it even more crucial to get the nation’s so-far underwhelming vaccine program on track.
9:56 a.m. Jan. 4, 2021 - By Ciara Linnane
U.S. heads toward 21 million COVID-19 cases and 353,000 deaths as vaccine program continues to lag all targets ‘Last mile’ vaccine distribution has been far slower than required, ‘with millions of doses still sitting on the shelves,’ says Raymond James analystThe global case tally for the coronavirus-borne illness COIVID-19 climbed above 85 million on Monday, as the U.S. headed toward 21 million cases and 353,000 deaths, as the vaccine program continued to advance with fits and starts and to lag all early targets.
6:44 a.m. Dec. 31, 2020 - By Ciara Linnane
U.S. sets record for COVID deaths, and California confirms second case of highly infectious new strain Operation Warp Speed officials acknowledge delays in distributing vaccines, experts say government must do more to help statesThe U.S. set fresh records for one-day fatalities from the coronavirus-borne illness COVID-19 and number of patients hospitalized, as California became the second state after Colorado to find a case of the new COVID-19 variant that is racing across the U.K.
9:23 a.m. Dec. 30, 2020 - By Ciara Linnane
U.S. sets record for COVID-19 hospitalizations, as country’s first case of new U.K. variant is found in Colorado Health experts continue to lament slow rollout of vaccines in U.S. after much-ballyhooed authorizations were granted in early December The U.S. set a fresh record for hospitalizations of patients with COVID-19 on Wednesday and the first case of the highly infectious U.K variant of the coronavirus was found in Colorado, as health experts continued to lament the delayed rollout of vaccines that is hampering the economic recovery.
7:14 a.m. Dec. 24, 2020 - By Tomi Kilgore
Daily death toll from COVID-19 climbs to more than 3,400, the same day vaccinations top 1 million Daily case count rise to more than 227,000 as hospitalizations jump again to a record for the 19th day this monthThe U.S. suffered through one of its worst days on the COVID-19 front since the pandemic started, with the daily death toll jumping to more than 3,400, on the same day it reached an “early but important” milestone of more than 1 million vaccinated.
6:38 a.m. Dec. 22, 2020 - By Nicole Lyn Pesce
Watch: Dr. Fauci gets Moderna’s COVID-19 vaccine on camera ‘as a symbol to the rest of the country’ to get vaccinated Fauci and HHS Secretary Alex Azar got their shots on camera so ‘Americans can be confident in this vaccine’ Fauci and HHS Secretary Alex Azar got the shot on camera so ‘Americans can be confident in this vaccine’
7:57 a.m. Dec. 14, 2020 - By Nicole Lyn Pesce
WATCH: Relieved Americans applaud as the Pfizer-BioNTech COVID-19 vaccine rolls out across the country Queens, N.Y., nurse Sandra Lindsay received the first COVID-19 vaccine in the U.S. on Monday morning Queens, N.Y., nurse Sandra Lindsay received the first COVID-19 vaccine in the U.S. on Monday morning
9:55 a.m. Dec. 11, 2020 - By Ciara Linnane
U.S. suffers its worst week of cases, deaths and hospitalizations since the start of the pandemic CDC head warns U.S. will see more deaths every day for next few months than died on Sept. 11, 2001, or in the attack on Pearl HarborThe U.S. suffered its worst week for cases, deaths and hospitalizations with the coronavirus illness COVID-19, as the Food and Drug Administration said it would grant emergency use authorization to the vaccine developed by Pfizer Inc. and its Germany partner BioNTech SE.
8:49 a.m. Dec. 7, 2020 - By Ciara Linnane
More than 101,000 COVID-19 patients are now in U.S. hospitals, and Dakotas lead nation in cases per capita ‘The vaccine’s critical. But it’s not going to save us from this current surge. Only we can save us from this current surge,’ says Dr. BirxThe U.S. set another record for hospitalizations with the coronavirus illness COVID-19 on Sunday, while case numbers and fatalities remained high, and the nation braced for what is expected to be a very dark winter.
6:46 a.m. Dec. 7, 2020 - By Andrew Keshner
Want your loved one in a nursing home to get a COVID-19 vaccine? Ask these questions first There are approximately 3 million people living in long-term care facilities, according to the CDCThere are approximately 3 million people living in long-term care facilities, according to the CDC.
10:00 a.m. Dec. 4, 2020 - By Ciara Linnane
CDC forecasts up to 19,500 deaths from COVID-19 in week ending Dec. 26 ‘People were less willing to change their behavior than any other day during the pandemic,’ data analyst says of Thanksgiving DayThe U.S. set yet another record for new cases and fatalities in a single day from the coronavirus illness COVID-19 and the nation’s leading public health agency said there could be up to 19,500 deaths in the week ended Dec. 26.
12:12 p.m. Dec. 3, 2020 - By Ciara Linnane
U.S. posts record one-day COVID death toll — before the predicted post-Thanksgiving surge December, January and February will be the ‘most difficult time in the public health history of this nation, largely because of the stress that it’s going to put on our health-care system,’ says CDC head Robert RedfieldThe U.S. hit some grim milestones in the coronavirus pandemic in a single day Wednesday, with a record number of fatalities and more than 100,000 COVID-19 patients in hospitals for the first time since the start of the outbreak, as a leading public health official warned of a cold, hard winter to come.
3:03 a.m. Dec. 3, 2020 - By Nicole Lyn Pesce
CDC director warns the next three months will be ‘the most difficult’ in public health history About 90% of U.S. hospitals are in ‘hot zones’ with high levels of coronavirus spread, Dr. Robert Redfield saysAbout 90% of U.S. hospitals are in ‘hot zones’ with high levels of coronavirus spread, Dr. Robert Redfield says
9:12 a.m. Dec. 2, 2020 - By Quentin Fottrell
‘Cytokine Storm’ — the ‘intriguing’ similarity between COVID-19 and the 1918 influenza A hyperinflammatory immune response to the influenza of 1918 was seen as one reason healthy people were so hard hit. How big a role has it played in 2020?A hyperinflammatory immune response to the influenza of 1918 was seen as one reason healthy people were so hard hit. How big a role has it played in 2020?
Browse topics:

Filter results by

Location

Us (217)

Europe (35)

Asia Pacific (34)

Eu (26)

China (15)

Latin America (13)

Link to MarketWatch's Slice.